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ABSTRACT Friend murine leukemia virus (Fr-MuLV) is
a replication-competent murine retrovirus that induces acute
nonlymphocytic leukemias in NFS/n mice. Fr-MuLV disease
is divided into two stages based on the ability of the leukemia
cells to grow in culture and transplant into syngeneic mice.
Hematopoietic cells taken from the early stage of disease after
Fr-MuLV infection grow as immortal myeloid cell lines in the
presence of WEHI-3 cell-conditioned medium (CM) or inter-
leukin 3. These growth factor-dependent cell lines do not grow
in culture in the absence of CM and do not form tumors in
syngeneic animals. If these Fr-MuLV-infected cells are super-
infected with Abelson murine leukemia virus (Ab-MuLV),
they lose their dependence on WEHI-3 CM and proliferate in
culture in the absence of exogenous growth factors. Concomi-
tant with the loss of growth factor dependence in culture, the
Ab-MuLV-infected cell lines become tumorigenic in syngeneic
mice. This secondary level of transformation is Ab-MuLV spe-
cific. Fr-MuLV-immortalized myeloid cell lines superinfected
with Harvey murine sarcoma virus (Ha-MuSV) or amphotro-
pic virus remain dependent on WEHI-3 CM for growth in vitro
and are not tumorigenic in vivo. Neither Ab-MuLV- nor Ha-
MuSV-infected normal mouse myeloid cell cultures produce
growth factor-independent or tumorigenic cell lines. We con-
clude that at least two genetic events are needed to convert a
murine myeloid precursor into a tumorigenic cell line. The
first event occurs in Fr-MuLV-infected mice, generating cells
that are growth factor dependent but immortal in vitro. The
second event, which can be accomplished by Ab-MuLV infec-
tion, converts these immortal myeloid precursors into growth
factor-independent and tumorigenic cells.
Friend murine leukemia virus (Fr-MuLV) is a replication-
competent type C retrovirus that induces a rapidly fatal
acute nonlymphocytic leukemia in NFS/n mice (1-3). Fr-
MuLV disease is divided into two stages based on the
growth properties of the virus-infected leukemia cells. Stage
I cells proliferate in diseased animals but will not transplant
into syngeneic mice. Stage I cells do not grow in culture un-
der standard cell culture techniques. Stage II cells are mor-
phologically indistinguishable from stage I cells. But stage II
cells will transplant into syngeneic animals and form contin-
uous cell lines in culture (4). The specific genetic events re-
sponsible for stage I and stage II transformation of hemato-
poietic precursors are unknown.
Hematopoietic cells obtained from mice with stage I leu-
kemia will grow as immortal cell lines if cultured in the pres-
ence of WEHI-3 cell-conditioned medium (CM) or interleu-
kin 3 (IL-3) (5). These cell lines are not identical to the Fr-
MuLV-infected leukemia cells found in mice. Fr-MuLV
disease in vivo manifests as an erythroleukemia. CM-depen-
dent cell lines grown in vitro consist of myeloblasts and other
elements of the myeloid cell lineage. However, these CM-
dependent myeloid cells exhibit growth properties similar to
the stage I erythroleukemia cells of mice. CM-dependent cell
lines do not form tumors in syngeneic mice, and they do not
grow in culture in the absence of CM. After >18 months in
culture, these cells remain absolutely dependent on CM for
proliferation. In an attempt to alter the growth factor re-
quirements of the CM-dependent cell lines, we superinfected
these cells with two acutely transforming retroviruses
Abelson murine leukemia virus (Ab-MuLV) and Harvey mu-
rine sarcoma virus (Ha-MuSV).
METHODS
Animals. NFS/n mice were originally obtained from the
small animal facility of the National Institutes of Health (Be-
thesda, MD). Subsequently, mice were bred by brother/sis-
ter matings in our own laboratory.
Cells. NIH 3T3 cells were obtained from the American
Type Culture Collection. WEHI-3 cells were a gift from Ed-
ward Scolnick of Merck Sharp & Dohme. Conditioned medi-
um from WEHI-3 cells was obtained 5 days after passag-
ing WEHI-3 cells in Dulbecco's modified Eagle's medium
(DME medium) with 10% fetal calf serum. WEHI-3 cells
were removed by centrifugation (1000 x g for 10 min), and
the clarified supernatant was frozen at -20'C until needed.
All CM-dependent cell lines were grown in DME medium
with 10% fetal calf serum and 10% WEHI-3 CM. Bone mar-
row cultures were established in 60-mm Petri dishes by
flushing the contents of two femurs into 5 ml of CM-depen-
dent cell line medium. These cultures were demi-depopulat-
ed every 3-4 days and fed with an equal volume of fresh
media.
Viruses. Fr-MuLV is a replication-competent, NB-tropic,
ecotropic, type C retrovirus obtained by transfection of mo-
lecularly cloned Fr-MuLV DNA into NIH 3T3 cells (2). Am-
photropic virus (designated "Ampho") is a replication-com-
petent, N-tropic, amphotropic, type C retrovirus obtained
by the transfection of molecularly cloned Ampho DNA into
NIH 3T3 cells (6). Ha-MuSV/Ampho and Ha-MuSV/Fr-
MuLV pseudotype viruses were prepared from an Ha-
MuSV-nonproducer NIH 3T3 cell (a gift from Douglas Lowy
of the National Cancer Institute) by superinfection with Am-
pho or Fr-MuLV virus, respectively. Virus stocks of Ha-
MuSV/Ampho contain 104 focus-forming units (ffu) of trans-
forming virus per ml of culture fluid as assayed on NIH 3T3
cells. Ha-MuSV/Fr-MuLV stocks contain 105 ffu/ml. Ab-
MuLV/Ampho and Ab-MuLV/Fr-MuLV pseudotype virus-
es were prepared from Ann-1 (7) Ab-MuLV-nonproducer
Abbreviations: Fr-MuLV, Friend murine leukemia virus; CM, con-
ditioned medium; IL-3, interleukin 3; Ab-MuLV, Abelson murine
leukemia virus; Ha-MuSV, Harvey murine sarcoma virus; ffu, fo-
cus-forming units.
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cells (a gift from Albert DeLeo of Sloan-Kettering Institute)
by superinfection with Ampho or Fr-MuLV virus, respec-
tively. Virus stocks of Ab-MuLV/Ampho and Ab-MuLV/
Fr-MuLV contain 104 and 105 ffu/ml of culture fluid, respec-
tively.
Animal Studies. Transplant recipients were injected intra-
venously with 106 viable cells; 2-5 weeks later, the mice
were sacrificed and their spleens were removed. Foci of tu-
mor cells were dissected out of the diseased spleens for fur-
ther analysis.
Preparation of cellular DNAs and RNAs and blot hybrid-
izations were performed as described (8). Molecular clones
of v-abl-specific sequences (pABl-9) and IL-3 cDNA se-
quences (pIL-3) used for probe synthesis were provided by
Stephen Goff of Columbia University and Hiam Aviv of Bio-
technology General, respectively. Reverse transcriptase as-
says were performed as described by Scolnick et al. (9).
RESULTS
Two CM-dependent cell lines were chosen for analysis. Sin-
gle-cell derivatives of these cell lines were isolated by soft-
agar cloning (103 and Elc) and were tested for the ability to
propagate in the absence of WEHI-3 CM. I03 and Elc cells
were removed from culture in mid-logarithmic-phase growth,
washed, and resuspended in fresh medium without CM. Af-
ter 3 days in suspension culture, no viable cells were visible.
After 3 weeks in soft-agar cultures, no colonies were pres-
ent. Parallel cultures of 103 and Elc cells suspended in medi-
um with CM yielded 1-2 x 106 viable cells per ml of suspen-
sion culture and 100-300 colonies per 106 cells plated in soft
agar with CM.
I03 and Elc are derived from Fr-MuLV-infected mice and
produce Fr-MuLV. Therefore, 103 and Elc cannot be super-
infected either by Fr-MuLV or by other ecotropic murine
leukemia viruses (10). To overcome this problem, we pre-
pared pseudotypes of Ab-MuLV and Ha-MuSV, using an
amphotropic murine retrovirus-Ampho (11). I03 and Elc
cells were removed from culture, washed, and resuspended
in fresh medium with CM and 104 ffu of Ab-MuLV/Ampho
or Ha-MuSV/Ampho or 105 infectious units ofAmpho virus.
After 1 week in culture with CM, the Ab-MuLV/Ampho-
and Ha-MuSV/Ampho-infected cells were assayed for
growth in the absence of CM. Suspension cultures of 103 and
Elc cells superinfected with Ab-MuLV/Ampho continued
to grow to high cell density (1-2 x 106 cells per ml) in the
absence of CM. These cells also produced dense colonies of
103 and Elc cells in soft agar without CM. However, the IO3
and Elc cells superinfected with Ha-MuSV/Ampho or Am-
pho alone did not grow in the absence of CM in suspension
cultures or in soft agar (Table 1).
To prove that the Ab-MuLV/Ampho and Ha-MuSV/Am-
pho viruses had infected the 103 and Elc cells, the culture
Table 1. Growth parameters of 103 and Elc cell lines
Continuous
growth in vitro
Cell Superinfecting With Without Tumorigenic
line virus CM CM in vivo ffu/ml*
103 + - - <1
Elc + - - <1
103 Ab-MuLV/Ampho + + + 100
Elc Ab-MuLV/Ampho + + + 100
103 Ha-MuSV/Ampho + - - 1000
Elc Ha-MuSV/Ampho + - - 1000
103 Ampho + - - <1
Elc Ampho + - - <1
*ffu titers were determined on NIH 3T3 cells with 0.5 ml of freshly
harvested culture fluid.
media from these cells were assayed for infectious focus-
forming virus on NIH 3T3 cells. Both the Ab-MuLV/Am-
pho- and Ha-MuSV/Ampho-superinfected I03 and Elc cells
produced focus-forming virus (Table 1). Focus-forming vi-
ruses were not detectable in culture media from untreated or
Ampho-superinfected I03 and Elc cells. To further analyze
the Ab-MuLV in the CM-independent 103 and Elc cells,
clonal isolates of these cell lines were prepared in soft-agar
cultures. Two such isolates (clones 1 and 4, designated cl-1
and cl-4) were picked and expanded in suspension culture.
High molecular weight DNA and poly(A)+ RNA was isolat-
ed from cl-1 and cl-4 cells and probed for the presence of Ab-
MuLV sequences. Southern blot analysis revealed multiple
Ab-MuLV bands in cl-1 and cl-4 that were not present in the
parental I03 cells (Fig. 1). Similarly, RNA blot analysis re-
vealed high levels of Ab-MuLV-specific transcripts in cl-1
and cl-4 cells (Fig. 2). Parallel filters hybridized with a mu-
rine leukemia virus long terminal repeat and gag probe rec-
ognized the same RNA species as did the abl probe (data not
shown). These studies indicate that Ab-MuLV is present and
is actively transcribed in cl-1 and cl-4.
Since I03 and Elc cells are dependent on IL-3 for growth
in culture, we asked if the growth factor-independent deriva-
tives of I03 and Elc make their own IL-3. Southern blot
analysis of the IL-3 gene locus in cl-1, cl-4, and I03 showed
the same pattern of bands comprising the IL-3 coding se-
quences in all three cell lines (Fig. 3). RNA dot-blot analysis
of poly(A)+ RNA from cl-1, c1-4, and I03 revealed the same
abundance of IL-3-specific sequences in the growth factor-
dependent and -independent cell lines (Fig. 4). These experi-
ments indicate that the IL-3 gene is not rearranged or ex-
pressed at elevated levels in Ab-MuLV/Ampho-infected fac-
tor-independent cells. To further test the possibility that
these cell lines produce a self-stimulating growth factor, CM
was prepared from cl-1 and c1-4 cells and tested for the abili-
ty to stimulate proliferation of two IL-3-dependent cell
lines-103 and FD (12). Cell proliferation was assayed by
viable cell counts and [3H]thymidine incorporation into cel-
lular DNA. Neither cl-1 nor cl-4 CM stimulated cell prolif-
eration in either I03 or FD cells (data not shown).
FIG. 1. Southern blot analysis of 103, cl-i, and cl-4 DNAs
probed with abl-specific sequences. Genomic DNA (10 ,g) from
each cell line was digested with EcoRI (lanes 1, 4, and 7), Xba I
(lanes 2, 5, and 8), and Ava I (lanes 3, 6, and 9) and were electropho-
resed through a 0.5% agarose gel at 35 V for 18 hr. The digested
DNAs were blot-transferred to nitrocellulose paper and hybridized
to nick-translated radiolabeled molecularly cloned abl DNA. Filter
washes were performed at high stringency: 0.1% NaDodSO4/0.015
M NaCl/0.0015 M sodium citrate, pH 7, at 55°C. Note the Ab-
MuLV bands present in cl-1 and cl-4 but absent from the uninfected
103. Size markers indicate the location of HindIII-digested wild-
type phage X DNA fragments (in kilobases) run in an adjacent lane.
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FIG. 2. RNA gel analysis of 103, cl-1, and cI-4 RNA probed with
abl-specific sequences. Poly(A)+ RNA (15 tig) was denatured in 2.2
M formaldehyde/50% formamide and electrophoresed through a
0.8% agarose/formaldehyde gel at 50 V for 18 hr. The RNAs were
blot-transferred to nitrocellulose paper and hybridized and washed
as in Fig. 1. Molecular size markers indicate the migration distances
of the 28S and 18S rRNAs present as contaminants in each prepara-
tion of poly(A)-selected RNA.
To test the tumorigenic potential of the growth factor-in-
dependent cell lines, 1 x 106 cl-1 or cl-4 cells were injected
intravenously into syngeneic mice. Control mice were inject-
ed with 1 x 106 I03, Elc, Ha-MuSV/Ampho-infected 103,
or Ampho-infected 103 cells. The mice injected with cl-1 and
cl-4 developed multiple macroscopic foci of tumor cells in
their spleens after 2-3 weeks. These tumor foci progressive-
ly enlarged, resulting in diffuse splenomegaly after 3-5
weeks. Microscopic examination of these spleens revealed
103 cl- c1-4








FIG. 3. Southern blot analysis of 103, cl-1, and cl-4 DNAs
probed with IL-3 cDNA. Genomic DNA (10 ,ug) from each cell line
was digested with EcoRI (lanes 1, 4, and 7), Xba I (lanes 2, 5, and 8),
and Ava I (lanes 3, 6, and 9). Electrophoresis and blot-transfer were
performed as in Fig. 1. Hybridization was performed by using a ra-
diolabeled nick-translated molecularly cloned IL-3 cDNA. Filter
washings were carried out as described in Fig. 1. Size markers indi-
cate the location of HindIII-digested wild-type phage X DNA frag-
ments (in kilobases) run in an adjacent lane.
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FIG. 4. RNA dot-blot analysis of 103, Elc, cl-1, c14, and WEHI-
3 cells probed with IL-3 cDNA. Poly(A)+ RNA (15 yg) was dena-
tured as described in Fig. 2 and dotted onto nitrocellulose paper by
using a Bethesda Research Labs dot-blot apparatus. Filter hybrid-
ization and washings were performed as described in Fig. 1.
>90% hematopoietic blasts replacing the normal spleen
cells. To prove that the tumor cells were of donor-cell origin
and not transformed host cells, the sex of the tumor cells was
determined by cytogenetics. cl-1 and cl-4 were derived from
male mice. The syngeneic animals used in this study were all
females. XY karyotypes were present in 17 of 25 metaphase
cells found in the diseased spleens. Thus, the majority of the
dividing cells in these spleens must be derived from the cl-1
or c1-4 cells injected into the female mice. None of the mice
injected with 103, Elc, Ha-MuSV/Ampho-infected I03, or
Ampho-infected 103 developed tumor foci or splenomegaly.
I03 and Elc are growth factor-dependent, immortal, my-
eloid cell lines obtained from leukemic mice. Ab-MuLV in-
fection converted these cell lines into growth factor-inde-
pendent tumorigenic cells. We next asked if Ab-MuLV in-
fection of normal myeloid cells grown under the same condi-
tions as I03 and Elc cells would also produce growth factor-
independent tumorigenic cells. Suspension cultures of nor-
mal mouse bone marrow were established in the presence of
WEHI-3 CM. The suspended cells were passaged twice
weekly into new culture dishes. After 1-2 weeks, this proc-
ess yielded a self-renewing population of myeloid cells in the
absence of attached cells or feeder layers. These cultures
consisted of 5-10% myeloblasts and 90-95% mature myeloid
elements (metamyelocytes, stabs, and mature granulocytes).
Myeloid cultures prepared in this manner exhibited the same
factor dependence for WEHI-3-CM as did 103 and Elc cells.
However, the myeloid cultures obtained from normal mouse
bone marrow are not immortal and invariably die out within
3-6 weeks. To evaluate the effect of Ab-MuLV infection on
these normal myeloid cells, four independently established
bone marrow cultures were infected with either Fr-MuLV or
Ampho pseudotypes of Ab-MuLV. Parallel cultures also
were infected with Ha-MuSV/Fr-MuLV, Ha-MuSV/Am-
pho, Fr-MuLV, or Ampho. Successful infection was moni-
tored by reverse transcriptase levels and the recovery of
focus-forming virus activity from the Ab-MuLV- and Ha-
MuSV-infected cultures. All six viruses successfully in-
fected the normal myeloid cultures (Table 2). However, no
CM-independent cell lines were established from these cul-
tures, and no tumor cell foci developed in the spleens of mice
injected with these cells.
103 and Elc are myeloid cell lines. The myeloid nature of
these cells was established by histochemical staining and
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Table 2. Growth parameters of normal myeloid cell cultures
Growth in vitro Tumorigenic Reverse
Infecting virus With CM Without CM in vivo transcriptase, cpm ffu/ml*
Ampho + - - 45,000 <1
Fr-MuLV + - - 62,000 <1
Ab-MuLV/Ampho + - - 36,000 100
Ab-MuLV/Fr-MuLV + - - 68,000 100
Ha-MuSV/Ampho + - - 27,000 100
Ha-MuSV/Fr-MuLV + - - 45,000 1000
None + - - 900 <1
*ffu titers were determined on NIH 3T3 cells with 0.5 ml of freshly harvested culture fluid.
morphologic examination (5). Exposure of 103 and Elc to
inducers of differentiation (e.g., 1.3% dimethyl sulfoxide or
2 mM hexamethylene bisacetamide) shifted these cell popu-
lations from 95-99% myeloblasts and 1-5% mature myeloid
elements to 50-60% myeloblasts and 40-50% mature cells.
Ab-MuLV-infected I03 and Elc cells retained this potential
for differentiation albeit to a lesser extent than did their pa-
rental cell lines. Dimethyl sulfoxide treatment of cl-1 and cl-4
shifted these cells from 99% myeloblasts and 1% mature my-
eloid elements to 75-85% myeloblasts and 15-25% mature
cells.
DISCUSSION
Friend virus-induced leukemias are divided into distinct
stages based on the growth properties of the leukemia cells
(13, 14). In the early stage (stage I disease) of leukemia, the
blast cells are unable to grow outside their normal hemato-
poietic environment (i.e., bone marrow or spleen). In the
late stage of leukemia (stage II disease), leukemia cells can
grow at any site in the mouse and will form continuous cell
lines in vitro (15). The genetic basis for this progression from
restricted to unrestricted cell growth is unclear. The present
study suggests that the activation of particular oncogenes
(e.g., abi) can alter the growth conditions for Fr-MuLV-im-
mortalized leukemia cells. It is possible that the tumor cell
progression seen in Fr-MuLV-induced leukemias (stage I to
stage II) is due to the sequential activation of several onco-
genes. As more oncogenes are activated, tumor cell growth
becomes less restricted and the cancer becomes more ag-
gressive. Although the implications of our observations for
human cancer are not clear, it is known that many human
cancer cells transcribe more than one oncogene (16-18). The
malignant phenotype may result from the combined effects
of these genes.
The case for a sequential effect of transforming genes in
the pathogenesis of fully malignant murine leukemia is fur-
ther substantiated by the observation that Ab-MuLV does
not convert myeloid cells obtained from normal mouse bone
marrow into CM-independent tumorigenic cell lines. At least
one other genetic change, in addition to expression of the abl
gene, is needed to transform myeloid precursors into tumori-
genic cells. Fr-MuLV-infected myeloid cell lines I03 and
Elc possess this additional genetic change since Ab-MuLV
infection transforms these cells into growth factor-indepen-
dent tumorigenic cell lines. It is unclear what this additional
genetic change is. However, Fr-MuLV infection per se is not
sufficient to alter the growth properties of normal myeloid
cell cultures. None of the normal myeloid cell cultures
grown in CM and infected with Fr-MuLV developed into im-
mortal cell lines (Table 2). Fr-MuLV is more likely needed to
activate an endogenous cellular oncogene via insertional mu-
tagenesis (19, 20). This type of Fr-MuLV-induced mutation
is likely to be a rare genetic event and may not occur during
the limited life span of normal myeloid cell cultures (3-6
weeks). However, in vivo many more myeloid precursors
are exposed to Fr-MuLV infection, thus increasing the likeli-
hood that Fr-MuLV will integrate near a critical gene in at
least one myeloid precursor.
Several investigators have shown that at least two onco-
genes are needed to transform primary mouse embryo fibro-
blasts into tumorigenic cells (21-23). One gene provides so
called "immortalizing" functions. The second gene is then
capable of inducing malignant cell transformation, but only
in the presence of the immortalizing gene. One or more of
these "immortalization" oncogenes may be activated in 103
and Elc cells.
Ab-MuLV and Ha-MuSV transform both fibroblasts and
hematopoietic cells in vitro and in vivo (24-31). Little is
known about the mechanism of cell transformation used by
these viruses. We have found that Ab-MuLV but not Ha-
MuSV converts IL-3-dependent myeloid cell lines into
growth factor-independent cells. Concomitant with the loss
of growth factor dependence, the Ab-MuLV-infected cells
become tumorigenic in syngeneic animals. This study sug-
gests that the cellular basis of Ab-MuLV-induced myeloid
cell transformation is elimination of the requirement for
growth factors for cell division. Ha-MuSV-induced hemato-
poietic cell transformation must be accomplished by a differ-
ent mechanism since Ha-MuSV-infected cell lines remain
dependent on WEHI-3 CM for cell proliferation. The molec-
ular basis of Ab-MuLV-induced IL-3 independence is un-
clear. However, analysis of cl-1 and c1-4 cells fails to support
the "autocrine" model of tumorigenesis (32). CM obtained
from these cells does not support the growth of hematopoiet-
ic factor-dependent cell lines. No evidence of altered IL-3
transcription or rearranged IL-3 DNA sequences is found in
cl-i or cl-4. Instead of triggering the production of IL-3, Ab-
MuLV appears to make IL-3 superfluous for cell prolifera-
tion.
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